Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking strategy to diabetes management. These innovative therapies work by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to consumption. By triggering GLP-1 receptors in the pancreas, these compounds enhance insulin secretion and reduce gluca

The burgeoning landscape of innovative treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting considerable weight decrease – they exhibit intriguing variations in the